Sanofi and Regeneron Pharmaceuticals announced positive results from two Phase IIIb/IV ODYSSEY-DM trials in patients with diabetes. In the studies,...
The emphasis in these Guidelines is to provide information on the current state of the art in how to prevent and manage the diverse problems associated with the effects of DM (Diabetes Mellitus) on the heart and vasculature in a holistic manner.
Background: Dietary potassium restriction is a strategy to control hyperkalemia in chronic kidney disease (CKD). However, hyperkalemia may result from a combination of clinical conditions. T
A new study on the effects of Lorqess (lorcaserin), from Eisai, for the treatment of Obesity shows positive results. The...
Corbus Pharma announced that they will proceed with a Phase III trial evaluating the efficacy and safety of lenabasum for...
Avanir Pharmaceuticals announced the results from the first study of the company's phase III clinical development program investigating the efficacy, safety and tolerability of AVP 786...
Background: In contrast with respiratory disease caused by influenza, information on the risk of respiratory syncytial virus (RSV) disease among adults with chronic medical conditions (CMCs) is limited.
Results from two subgroup analyses of the Phase IV independent TWILIGHT trial funded by AstraZeneca showed Brilinta (ticagrelor) monotherapy reduced the risk of clinically relevant bleeding over 12 months compared to aspirin plus Brilinta in high-risk coronary patients.